2003

Grasty RC, Grey BE, Wolf DC,  Lau CS, Rogers JM. 2003. Prenatal window of susceptibility to perfluorooctane sulfonate-induced neonatal mortality in the Sprague-Dawley rat. Birth Defects Res (Part B) Dev Reprod ToxicolDec;68(6):465-71.

Luippold RS, Mundt KA, Austin RP, Liebig E, Panko JP, Crump C, Crump K, Proctor DM. 2003. Lung cancer mortality among chromate workers. 2003. Occup Environ Med. 60:451−457.

Proctor D, Panko J, Liebig E, Mundt K, Buczynski M, Barnhart R, Harris MA, Morgan R, Finley B, and Paustenbach D. 2003. Workplace concentrations of airborne hexavalent chromium for the Painesville, Ohio chromate production plant. Appl Occ Environ Hyg J. 18(6):430-449.

Scott P, Petura J, and Harris MA. 2003. Derivation of a liquid to solid ratio for ASTM method D3987 85 for soils containing chromite ore processing residue using selected unsaturated zone models. Soil Sed Contam. 12(4):443-480.

2002

Grant RL, Rodriguez R, Hofelt CS, and Haws LC. 2002. Shortcomings in USEPA’s approach for predicting risk due to consumption of animal food products impacted by air emissions from hazardous waste combustion facilities: a case study involving phthalates. Human Ecol Risk Assess. 8(5):1137-1154.

Roberts SM, Jordan KE, Warren DA, Britt JK and James RC. 2002. Evaluation of the carcinogenicity of 1,1-Dichloroethylene (Vinylidene Chloride). Regul. Toxicol. Pharmacol. 35:44-55.

Merok, JR, Lansita, JA, Tunstead, JR, Sherley, JL. 2002. “Cosegregation of Chromosomes Containing Immortal DNA Strands in Cells that Cycle with Asymmetric Stem Cell Kinetics,” Cancer Res., 62, 6791-6795.

Hofelt CS, Honeycutt M, McCoy JT, and Haws LC. 2001. Development of a metabolism factor for polycyclic aromatic hydrocarbons for use in multipathway risk assessments for hazardous waste combustion facilities. Reg Toxicol Pharmacol. 33:60-65.

Strobel HW, Thompson CM, Antonovic L. 2001. Cytochromes P450 in brain: function and significance. Current Drug Metabolism. 2(2), 199–214.

Lea IA, Widgren EE, O’Rand MG. 2002. Analysis of recombinant mouse zona pellucida protein 2 (ZP2) constructs for immunocontraception. Vaccine 20(11–12):1515–1523

View Abstract